Apivar 500 mg Bee-hive Strips for Honey Bees

Страна: Велика Британія

мова: англійська

Джерело: VMD (Veterinary Medicines Directorate)

Активний інгредієнт:

Amitraz

Доступна з:

Veto-Pharma

ІПН (Міжнародна Ім'я):

Amitraz

Фармацевтична форма:

Bee-hive strip

Тип рецепту:

AVM-GSL - Authorised Veterinary Medicine – General Sales List

Терапевтична група:

Honey bees

Терапевтична области:

Ectoparasiticide

Статус Авторизація:

Authorized

Дата Авторизація:

2017-09-15

Характеристики продукта

Revised: July 2022
AN: 02695/2021
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Apivar 500 mg bee-hive strips for honey bees
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 15g strip contains:
ACTIVE SUBSTANCE:
Amitraz…………………………………….500 mg
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Bee-hive strips.
Rectangular translucent homogeneous rigid strip with a V-shape cutting
at one end
and a hole above. Strips are attached by two with a pre-cut line.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Honey bees
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of varroosis due to _Varroa destructor_ sensitive to amitraz
in honey bees.
4.3
CONTRAINDICATIONS
Do not use in case of known resistance to amitraz.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
It is recommended not to use the product during the honey flow but
after the honey
harvest. See section “Amount to be administered and administration
route”.
Do not cut the strips.
All colonies in the same apiary should be treated simultaneously to
avoid
reinfestation.
Do not re-use the strips.
The safety and efficacy of the product has only been investigated in
hives with a
single brood chamber (dose of 2 strips per hive/brood chamber). Use in
hives with
more than one brood chamber is not recommended.
Inappropriate use of the product could result in an increased risk of
resistance
development and could ultimately result in ineffective therapy.
Bee colonies should be monitored routinely for the level of varroa
mite infestation,
specifically before the treatment and for a period thereafter.
Revised: July 2022
AN: 02695/2021
Page 2 of 5
The product should be used as part of an integrated varroa control
program and
treatment rotation should be applied.
Amitraz resistance has been reported in some populations of Varroa
mites.
In case of use in regions with suspected amitraz resistance, it is
recommended that
the use of the product should be based on res